Agents at the Peak of US FDA Approval for the Treatment of Alzheimer's Disease.

Where Alzheimer's disease (AD) is becoming a global health issue, the present anti-AD medications have also been exposed to produce only symptomatic outcomes. The pathological factors, like neuronal transmission impairment, amyloidal-tau constituents, oxidative damage, neuro-inflammation, synaptic dysfunction, infectious agents, and impairment of gut microbiota and vitamins' levels; all favor the disease's progression and sustainability. The researchers have investigated several drugable molecules against these factors; however, no treatment could have been discovered yet to prevent the disease's progression rather than anti-amyloidal antibodies. After a comprehensive review of the literature and the clinical registry (clinicaltrials.gov), the authors of this manuscript have explored drug molecules that are under phase-3 of clinical trials and at the peak of getting approval for the management of AD. The inclusion and exclusion criteria for clinical trials were decided by considering the basis of a drug's approval. We included only the clinical trials were found in stages of Enrolling-by-Invitation, Recruiting, Not Recruiting (But active), and Not Recruiting (Not active) while excluding Completed, Terminated, Suspended, Withdrawn, or the trials of Unknown Status. We have found many potent drug molecules reached the clinical trials in phase-3 that could be futuristic anti-AD agents. This review article aims to provide an update on the prospective potential anti-AD medicines and to reveal the therapeutic targets of great significance for designing further a possible drug development strategy against AD pathology.

Standard of reporting animal-based experimental research in Indian Journal of Pharmacology.

OBJECTIVE: The objective of present study was to survey and determine the reporting standards of animal studies published during three years from 2012 to 2014 in the Indian Journal of Pharmacology (IJP). MATERIAL AND METHODS: All issues of IJP published in the year 2012, 2013 and 2014 were reviewed to identify animal studies. Each animal study was searched for 15 parameters specifically designed to review standards of animal experimentation and research methodology. OBSERVATION: All published studies had clearly defined aims and objectives while a statement on ethical clearance about the study protocol was provided in 97% of papers. Information about animal strain and sex was given in 91.8% and 90% of papers respectively. Age of experimental animals was mentioned by 44.4% papers while source of animals was given in 50.8% papers. Randomization was reported by 37.4% while 9.9% studies reported blinding. Only 3.5% studies mentioned any limitations of their work. CONCLUSION: Present study demonstrates relatively good reporting standards in animal studies published in IJP. The items which need to be improved are randomization, blinding, sample size calculation, stating the limitations of study, sources of support and conflict of interest. The knowledge shared in the present paper could be used for better reporting of animal based experiments.

Use of serotonergic antidepressants and St John's wort in older Australians: a population-based cohort study.

OBJECTIVE: The study investigated the use of serotonergic antidepressants (SSRIs: selective serotonin reuptake inhibitors; SNRIs: serotonin-norepinephrine reuptake inhibitors) and St John's wort in a large NSW-based community sample, and sought to identify a potentially dangerous concomitant use of these medications. METHODS: Cross-sectional data from 266,848 participants from the '45 and Up' study were used. The questionnaire captures self-reported treatment for depression or anxiety and antidepressant medications in the last four weeks. RESULTS: 5.8% of participants received treatment for depression or anxiety, with 4.7% taking an SSRI and 1.3% an SNRI. St John's wort was taken by 0.3% of the participants. Use of SSRIs and SNRIs was reported more frequently by females than males (respectively, 64.1% vs 35.9%, 66.9% vs 33.1%). The gender difference was even more pronounced for St John's wort (75.6% vs. 24.4%). Use of antidepressants decreased after the age of 65 years. One hundred and forty people reported concurrent use of an SSRI and an SNRI, and 11 people of an SSRI with St John's wort. CONCLUSIONS: Around 7% of the study population aged 45-65 years reported the use of SSRIs or SNRIs, decreasing to 5% above 70 years of age. It is of concern that some individuals used an SSRI concurrently with St John's wort.

Phytochemical analysis, cytotoxic activity and constituents-activity relationships of the leaves of Cinnamomum iners (Reinw. ex Blume-Lauraceae).

The leaves of Cinnamomum iners (Reinw. ex Blume-Lauraceae) have been refluxed successively with chloroform and alcohol to get chloroform extract and alcoholic extract. Both the extracts have been assayed for cytotoxicity against human colorectal tumour cells. The chloroform extract exhibited significant cytotoxicity with IC(50) 31 µg mL(-1) (p < 0.01). However, ethanol extract was found to be much less cytotoxic with IC(50) > 200 µg mL(-1). The chloroform extract has been further proceeded for chemical analysis by GC-TOFMS and 178 components were identified including acids, amines, amides, aldehydes, alcohols, esters, benzene derivatives, bicyclic compounds, terpenes, hydrocarbons, naphthalene derivatives, furan derivatives, azulenes, etc. Nine components representing 51.73% of the total chloroform extract were detected as major components. Caryophyllene (14.41%) and Eicosanoic acid ethyl ester (12.17%) are the most prominent components of the chloroform extract. ß-Caryophyllene (14.41%) as most abundant compound supports potent cytotoxicity as shown by chloroform extract.

A novel lupene-type triterpenic glucoside from the leaves of Clerodendrum inerme.

A new triterpenic glucoside, lup-1,5,20(29)-trien-3-O-beta-D-glucopyranoside (4), along with three known phytoconstituents: n-octacosane, friedelin and beta-amyrin, has been isolated from the leaves of Clerodendrum inerme (L.) Gaertn. (Verbenaceae). Structure elucidation was carried out on the basis of chemical and physical evidence (IR, 1H-NMR, 13C-NMR, DEPT and MS spectra). The alcoholic and aqueous extracts of the leaves of C. inerme showed significant antinociceptive activity in analgaesiometer tests.

Pharmacoenvironmentology--a component of pharmacovigilance.

According to WHO, Pharmacovigilance activities are done to monitor detection, assessment, understanding and prevention of any obnoxious adverse reactions to drugs at therapeutic concentration on animal and human beings. However, there is also a growing focus among scientists and environmentalists about the impact of drugs on environment and surroundings. The existing term 'Ecopharmacology' is too broad and not even defined in a clear manner. The term 'Pharmacoenvironmentology' seeks to deal with the environmental impact of drugs given to humans and animals at therapeutic doses.